In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Do Dx-Life Science Synergies Exist? Beckman Says 'You Bet They Do'

Executive Summary

Life sciences and clinical diagnostics seem to have a lot in common, but their customer needs, margins and product life cycles differ significantly. Beckman Coulter, one of the few large diagnostics companies with significant life science commitments, argues vociferously in favor of the strategic value of leveraging both businesses, despite many difficulties. Its MHC tetramer program is a prime example of its strategy.

You may also be interested in...



How Big Can Bio-Rad Get?

Bio-Rad's having a great year, thanks to its presence in the fast-growing life sciences business of protein analysis, and its surprise success with a test for bovine spongiform encephalopathy (BSE). Founder and CEO David Schwartz built the business based on a mix of eclectic product lines into an $800 million force in life sciences and clinical diagnostics. But as he nears 80, the company is grappling with succession issues, as well as a sense that it needs to better integrate its disparate businesses.

Beckman Coulter's Play for High Growth

With the Coulter integration successful, Beckman Coulter looks for high-growth opportunities outside of its traditional businesses. Beckman, through internal efforts in its life sciences business and a series of small alliances, is making a play in genomics and proteomics. In addition to building up near-term revenues, the aim is to find new "content" in the form of assays for its clinical business.

BioRx and BioDx: Can the Two Businesses Mix?

Few biotech companies venture into diagnostics, largely because they believe that therapeutics and diagnostics don’t mix. However, a handful of biotech/ small pharmaceutical companies are active in diagnostics and therapeutics, taking largely one of two approaches: using diagnostics to obtain near-term cash flow or as an integral part of a broader strategy in disease management.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC142222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel